ニュース

With an upside potential of 21.26% as of May 3, Merck & Co., Inc. (NYSE:MRK) is included among the 10 Best Fortune 500 Stocks to Buy According to Analysts. Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies, and animal health products. […]

EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash

Wondering whether Merck’s current share price reflects its real value, or if the stock might be pricing in more than it should. Merck closed at US$113.15, with returns of 2.8% over 7 days, a 6.4% decline over 30 days, 6.3% year to date and 48.4% over the last year. Recent headlines around Merck have kept investors focused on how the company is being priced, with attention on its long term prospects and capital allocation decisions. This context helps explain why the stock’s recent moves have...

AMD upgraded, Reddit downgraded: Wall Street's top analyst calls

Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he

The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of